Journal ArticleDOI
Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics
Reads0
Chats0
TLDR
The current case highlights the potential risk of lactobacilli translocation in an immunosuppressed patient with ulcerative colitis taking probiotics.Abstract:
A man in his 60s presented to the emergency room with fever and fatigue after a 2.5-month course of corticosteroids. His medical history was significant for bioprosthetic aortic valve replacement and moderately severe ulcerative colitis treated with balsalazide and daily lactobacillus-containing probiotics. Initial investigations revealed Lactobacillus rhamnosus bacteraemia without complication. Four days after hospital discharge, the patient experienced acute-onset right-sided paraesthesia and lower-limb paresis. On return to the emergency room, MRI of the brain demonstrated innumerable ring-enhancing lesions with haemorrhagic transformation. Transoesophageal echocardiogram revealed a small mobile density on the bioprosthetic aortic valve, raising the suspicion for L. rhamnosus infective endocarditis with secondary septic emboli to the brain. The patient was subsequently treated with intravenous gentamycin and ampicillin, with transition to indefinite oral amoxicillin suppressive therapy. The current case highlights the potential risk of lactobacilli translocation in an immunosuppressed patient with ulcerative colitis taking probiotics.read more
Citations
More filters
Journal ArticleDOI
Use of Bacteriocins and Bacteriocinogenic Beneficial Organisms in Food Products: Benefits, Challenges, Concerns
TL;DR: This review’s objective was to critically revisit various research approaches for studies on the application of beneficial organisms and bacteriocins as effective biopreservatives in the food industry.
Journal ArticleDOI
Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 17: suitability of taxonomic units notified to EFSA until September 2022
Konstantinos Koutsoumanis,Ana Allende,Avelino Alvarez-Ordóñez,Declan Bolton,Sara Bover-Cid,Marianne Chemaly,Alessandra De Cesare,Friederike Hilbert,Roland Lindqvist,Maarten Nauta,Luísa Peixe,Giuseppe Ru,Marion Simmons,Panagiotis N. Skandamis,Elisabetta Suffredini,Pier Sandro Cocconcelli,Pablo Salvador Fernández Escámez,Miguel Prieto Maradona,Amparo Querol,Lolke Sijtsma,Juan E. Suárez,Ingvar Sundh,Just M. Vlak,Fulvio Barizzone,Sandra Correia,Lieve Herman +25 more
TL;DR: The qualified presumption of safety (QPS) approach was developed to provide a regularly updated generic pre-evaluation of the safety of microorganisms intended for use in the food or feed chains, to support the work of EFSA's Scientific Panels as mentioned in this paper .
References
More filters
Journal ArticleDOI
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
Daniel N. Frank,Allison L. St. Amand,Robert A. Feldman,Edgar C. Boedeker,Noam Harpaz,Norman R. Pace +5 more
TL;DR: Patient stratification by GI microbiota provides further evidence that CD represents a spectrum of disease states and suggests that treatment of some forms of IBD may be facilitated by redress of the detected microbiological imbalances.
Journal ArticleDOI
Unravelling the pathogenesis of inflammatory bowel disease
TL;DR: Recently, substantial advances in the understanding of the molecular pathogenesis of inflammatory bowel disease (IBD) have been made owing to three related lines of investigation as mentioned in this paper, which have shown the importance of epithelial barrier function, and innate and adaptive immunity in disease pathogenesis.
Journal ArticleDOI
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease
S. J. Ott,Meike Musfeldt,D F Wenderoth,Jochen Hampe,O Brant,Ulrich R. Fölsch,Kenneth N. Timmis,Stefan Schreiber +7 more
TL;DR: Mucosal inflammation in inflammatory bowel disease is associated with loss of normal anaerobic bacteria, independent of NOD2/CARD15 status of patients.
Journal ArticleDOI
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Wolfgang Kruis,Fric P,J Pokrotnieks,Milan Lukas,B Fixa,M Kaščák,Michael A. Kamm,J Weismueller,Christoph Beglinger,M Stolte,C Wolff,J Schulze +11 more
TL;DR: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis, which underlines the pathogenetic significance of the enteric flora.
Journal ArticleDOI
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
TL;DR: The results suggest that treatment with a non-pathogenic E. coli has an equivalent effect to mesalazine in maintaining remission of ulcerative colitis.